NO330012B1 - Pyrrolidonderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat inneholdende slike, slike forbindelser for behandling av sykdom samt anvendelse av slike for fremstilling av medikament for behandling av sykdom - Google Patents
Pyrrolidonderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat inneholdende slike, slike forbindelser for behandling av sykdom samt anvendelse av slike for fremstilling av medikament for behandling av sykdom Download PDFInfo
- Publication number
- NO330012B1 NO330012B1 NO20050665A NO20050665A NO330012B1 NO 330012 B1 NO330012 B1 NO 330012B1 NO 20050665 A NO20050665 A NO 20050665A NO 20050665 A NO20050665 A NO 20050665A NO 330012 B1 NO330012 B1 NO 330012B1
- Authority
- NO
- Norway
- Prior art keywords
- phenyl
- oxo
- pyrrolidine
- carboxylic acid
- benzyloxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 86
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 230000008569 process Effects 0.000 title claims abstract description 6
- 201000010099 disease Diseases 0.000 title claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 5
- 150000001875 compounds Chemical class 0.000 title claims description 125
- 239000003814 drug Substances 0.000 title claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 150000004040 pyrrolidinones Chemical class 0.000 title description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 11
- 229940052764 dopaminergic anti-parkinson drug mao b inhibitors Drugs 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 4
- 230000001404 mediated effect Effects 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 53
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 claims description 38
- 239000001257 hydrogen Substances 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 229910052736 halogen Inorganic materials 0.000 claims description 32
- 150000002367 halogens Chemical class 0.000 claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 28
- -1 cyano, methoxy Chemical group 0.000 claims description 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 13
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 11
- LTIYXUCBPYAJFG-CQSZACIVSA-N (3r)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1C[C@@H](C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=CC(F)=C1 LTIYXUCBPYAJFG-CQSZACIVSA-N 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 150000001412 amines Chemical class 0.000 claims description 8
- 125000004970 halomethyl group Chemical group 0.000 claims description 7
- 230000007306 turnover Effects 0.000 claims description 7
- 150000002825 nitriles Chemical class 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- HXRHHIADVPTANH-CQSZACIVSA-N (3r)-1-[4-[(4-fluorophenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1C[C@@H](C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=C(F)C=C1 HXRHHIADVPTANH-CQSZACIVSA-N 0.000 claims description 5
- PYEFTQXAXYXRER-UHFFFAOYSA-N 1-[2-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C(=C1)F)=CC=C1OCC1=CC=CC(F)=C1 PYEFTQXAXYXRER-UHFFFAOYSA-N 0.000 claims description 5
- XJDPWKQDJRKDMJ-UHFFFAOYSA-N 1-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1F)=CC=C1OCC1=CC=CC(F)=C1 XJDPWKQDJRKDMJ-UHFFFAOYSA-N 0.000 claims description 5
- GDWRWQPBVGFRJK-UHFFFAOYSA-N 1-[4-[(3-fluorophenyl)methoxy]-3-methylphenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1C)=CC=C1OCC1=CC=CC(F)=C1 GDWRWQPBVGFRJK-UHFFFAOYSA-N 0.000 claims description 5
- AVJRBMQFHVQJES-VOTSOKGWSA-N 1-[4-[(e)-2-(3-methoxyphenyl)ethenyl]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1\C=C\C1=CC=CC(OC)=C1 AVJRBMQFHVQJES-VOTSOKGWSA-N 0.000 claims description 5
- XBCSUOWYPCXSOZ-UHFFFAOYSA-N 1-[6-[(4-fluorophenyl)methoxy]pyridin-3-yl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=N1)=CC=C1OCC1=CC=C(F)C=C1 XBCSUOWYPCXSOZ-UHFFFAOYSA-N 0.000 claims description 5
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 5
- ZCQOOZQGELHELR-OAHLLOKOSA-N (3r)-n-methyl-5-oxo-1-(4-phenylmethoxyphenyl)pyrrolidine-3-carboxamide Chemical compound O=C1C[C@@H](C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=CC=C1 ZCQOOZQGELHELR-OAHLLOKOSA-N 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- UNOGAMFUIQYPBC-UHFFFAOYSA-N 1-[4-[(2-methoxyphenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=CC=C1OC UNOGAMFUIQYPBC-UHFFFAOYSA-N 0.000 claims description 4
- MXSCXPANVAFQFT-UHFFFAOYSA-N 1-[4-[(3-chlorophenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=CC(Cl)=C1 MXSCXPANVAFQFT-UHFFFAOYSA-N 0.000 claims description 4
- DTIKYBBSQWNTMA-UHFFFAOYSA-N 1-[4-[(3-cyanophenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=CC(C#N)=C1 DTIKYBBSQWNTMA-UHFFFAOYSA-N 0.000 claims description 4
- LTIYXUCBPYAJFG-UHFFFAOYSA-N 1-[4-[(3-fluorophenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=CC(F)=C1 LTIYXUCBPYAJFG-UHFFFAOYSA-N 0.000 claims description 4
- RRJHKZYWZMNUKR-UHFFFAOYSA-N 1-[4-[(3-methoxyphenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=CC(OC)=C1 RRJHKZYWZMNUKR-UHFFFAOYSA-N 0.000 claims description 4
- CWTPDWFQLYCQOA-ONEGZZNKSA-N 1-[4-[(e)-2-(4-methoxyphenyl)ethenyl]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1\C=C\C1=CC=C(OC)C=C1 CWTPDWFQLYCQOA-ONEGZZNKSA-N 0.000 claims description 4
- OJSCIDIPCZNXCE-UHFFFAOYSA-N 1-[4-[2-(3-fluorophenyl)ethyl]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1CCC1=CC=CC(F)=C1 OJSCIDIPCZNXCE-UHFFFAOYSA-N 0.000 claims description 4
- URQLWOGBXRYQLN-UHFFFAOYSA-N 1-[4-[2-(3-methoxyphenyl)ethyl]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1CCC1=CC=CC(OC)=C1 URQLWOGBXRYQLN-UHFFFAOYSA-N 0.000 claims description 4
- XNOMMRSKFOSIDX-UHFFFAOYSA-N 1-[4-[2-(4-chlorophenyl)ethyl]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1CCC1=CC=C(Cl)C=C1 XNOMMRSKFOSIDX-UHFFFAOYSA-N 0.000 claims description 4
- BJNJDYNFIRLJTG-UHFFFAOYSA-N 1-[4-[2-(4-fluorophenyl)ethyl]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1CCC1=CC=C(F)C=C1 BJNJDYNFIRLJTG-UHFFFAOYSA-N 0.000 claims description 4
- WQDLQJHRWYLROW-UHFFFAOYSA-N 2-[1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxopyrrolidin-3-yl]acetonitrile Chemical compound FC1=CC=CC(COC=2C=CC(=CC=2)N2C(CC(CC#N)C2)=O)=C1 WQDLQJHRWYLROW-UHFFFAOYSA-N 0.000 claims description 4
- PNGZXOGBYNEAOD-UHFFFAOYSA-N 2-[5-oxo-1-(4-phenylmethoxyphenyl)pyrrolidin-3-yl]acetonitrile Chemical compound O=C1CC(CC#N)CN1C(C=C1)=CC=C1OCC1=CC=CC=C1 PNGZXOGBYNEAOD-UHFFFAOYSA-N 0.000 claims description 4
- 230000006806 disease prevention Effects 0.000 claims description 4
- ZCQOOZQGELHELR-UHFFFAOYSA-N n-methyl-5-oxo-1-(4-phenylmethoxyphenyl)pyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=CC=C1 ZCQOOZQGELHELR-UHFFFAOYSA-N 0.000 claims description 4
- XIOGEEVSVGYVGV-UHFFFAOYSA-N n-methyl-5-oxo-1-[4-[(3,4,5-trifluorophenyl)methoxy]phenyl]pyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC(F)=C(F)C(F)=C1 XIOGEEVSVGYVGV-UHFFFAOYSA-N 0.000 claims description 4
- KOEOEXAFAKXZNM-UHFFFAOYSA-N n-methyl-5-oxo-1-[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]pyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=CC(C(F)(F)F)=C1 KOEOEXAFAKXZNM-UHFFFAOYSA-N 0.000 claims description 4
- ZCQOOZQGELHELR-HNNXBMFYSA-N (3s)-n-methyl-5-oxo-1-(4-phenylmethoxyphenyl)pyrrolidine-3-carboxamide Chemical compound O=C1C[C@H](C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=CC=C1 ZCQOOZQGELHELR-HNNXBMFYSA-N 0.000 claims description 3
- GXTXIWVOLSMYBY-UHFFFAOYSA-N 1-[4-[(3-chlorophenyl)methoxy]-3-methylphenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1C)=CC=C1OCC1=CC=CC(Cl)=C1 GXTXIWVOLSMYBY-UHFFFAOYSA-N 0.000 claims description 3
- WGBYXUMCYLXBOZ-UHFFFAOYSA-N 1-[4-[(2-fluorophenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=CC=C1F WGBYXUMCYLXBOZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- ZRBKGDXNEWYYNM-UHFFFAOYSA-N n-methyl-5-oxo-1-[4-[(2,3,4-trifluorophenyl)methoxy]phenyl]pyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=C(F)C(F)=C1F ZRBKGDXNEWYYNM-UHFFFAOYSA-N 0.000 claims description 2
- LXVAJBHGISGUBF-UHFFFAOYSA-N n-methyl-5-oxo-1-[4-[(2,4,6-trifluorophenyl)methoxy]phenyl]pyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=C(F)C=C(F)C=C1F LXVAJBHGISGUBF-UHFFFAOYSA-N 0.000 claims description 2
- 125000000301 2-(3-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- COPVGBIHILMFJH-UHFFFAOYSA-N n-methyl-2-oxopyrrolidine-3-carboxamide Chemical compound CNC(=O)C1CCNC1=O COPVGBIHILMFJH-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 128
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 70
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- 239000000243 solution Substances 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 102000010909 Monoamine Oxidase Human genes 0.000 description 28
- 108010062431 Monoamine oxidase Proteins 0.000 description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 238000005804 alkylation reaction Methods 0.000 description 24
- 230000029936 alkylation Effects 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 21
- 238000000746 purification Methods 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 20
- LNCZWDCYTJRWGX-UHFFFAOYSA-N methyl 1-(4-hydroxyphenyl)-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C1=CC=C(O)C=C1 LNCZWDCYTJRWGX-UHFFFAOYSA-N 0.000 description 19
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 17
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 17
- 238000010626 work up procedure Methods 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
- 239000003054 catalyst Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 238000007098 aminolysis reaction Methods 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 229910052731 fluorine Inorganic materials 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- RZQMFZBILLDSRX-UHFFFAOYSA-N 5-oxo-1-(4-phenylmethoxyphenyl)pyrrolidine-3-carboxylic acid Chemical compound O=C1CC(C(=O)O)CN1C(C=C1)=CC=C1OCC1=CC=CC=C1 RZQMFZBILLDSRX-UHFFFAOYSA-N 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000009833 condensation Methods 0.000 description 9
- 230000005494 condensation Effects 0.000 description 9
- 239000011737 fluorine Substances 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 230000032050 esterification Effects 0.000 description 8
- 238000005886 esterification reaction Methods 0.000 description 8
- 238000005984 hydrogenation reaction Methods 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- RUJXEUUQFZVPDT-CYBMUJFWSA-N (3r)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1C[C@@H](C(=O)O)CN1C(C=C1)=CC=C1OCC1=CC=CC(F)=C1 RUJXEUUQFZVPDT-CYBMUJFWSA-N 0.000 description 7
- RZQMFZBILLDSRX-CQSZACIVSA-N (3r)-5-oxo-1-(4-phenylmethoxyphenyl)pyrrolidine-3-carboxylic acid Chemical compound O=C1C[C@@H](C(=O)O)CN1C(C=C1)=CC=C1OCC1=CC=CC=C1 RZQMFZBILLDSRX-CQSZACIVSA-N 0.000 description 7
- RUJXEUUQFZVPDT-ZDUSSCGKSA-N (3s)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1C[C@H](C(=O)O)CN1C(C=C1)=CC=C1OCC1=CC=CC(F)=C1 RUJXEUUQFZVPDT-ZDUSSCGKSA-N 0.000 description 7
- RZQMFZBILLDSRX-AWEZNQCLSA-N (3s)-5-oxo-1-(4-phenylmethoxyphenyl)pyrrolidine-3-carboxylic acid Chemical compound O=C1C[C@H](C(=O)O)CN1C(C=C1)=CC=C1OCC1=CC=CC=C1 RZQMFZBILLDSRX-AWEZNQCLSA-N 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- LNCZWDCYTJRWGX-MRVPVSSYSA-N methyl (3r)-1-(4-hydroxyphenyl)-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1C[C@@H](C(=O)OC)CN1C1=CC=C(O)C=C1 LNCZWDCYTJRWGX-MRVPVSSYSA-N 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- FORMFFDDQMCTCT-UHFFFAOYSA-N 1-(diethoxyphosphorylmethyl)-4-nitrobenzene Chemical compound CCOP(=O)(OCC)CC1=CC=C([N+]([O-])=O)C=C1 FORMFFDDQMCTCT-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000005903 acid hydrolysis reaction Methods 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 6
- LJKNSNCOMDURFB-UHFFFAOYSA-N 1-(4-hydroxy-3-methylphenyl)-5-oxopyrrolidine-3-carboxylic acid Chemical compound C1=C(O)C(C)=CC(N2C(CC(C2)C(O)=O)=O)=C1 LJKNSNCOMDURFB-UHFFFAOYSA-N 0.000 description 5
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 5
- BYDMSBAYJNTXCL-UHFFFAOYSA-N 5-oxo-1-(4-phenylmethoxyphenyl)pyrrolidine-3-carbonyl chloride Chemical compound O=C1CC(C(=O)Cl)CN1C(C=C1)=CC=C1OCC1=CC=CC=C1 BYDMSBAYJNTXCL-UHFFFAOYSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- UBUBLQQZNPQHBG-UHFFFAOYSA-N methyl 1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC=CC(F)=C1 UBUBLQQZNPQHBG-UHFFFAOYSA-N 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- SHLKNRWKCSBHDX-GFCCVEGCSA-N (3r)-1-[4-[(2,6-difluorophenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1C[C@@H](C(=O)NC)CN1C(C=C1)=CC=C1OCC1=C(F)C=CC=C1F SHLKNRWKCSBHDX-GFCCVEGCSA-N 0.000 description 4
- LTIYXUCBPYAJFG-AWEZNQCLSA-N (3s)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1C[C@H](C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=CC(F)=C1 LTIYXUCBPYAJFG-AWEZNQCLSA-N 0.000 description 4
- SCBZBMXPJYMXRC-UHFFFAOYSA-N 1-(bromomethyl)-3-fluorobenzene Chemical compound FC1=CC=CC(CBr)=C1 SCBZBMXPJYMXRC-UHFFFAOYSA-N 0.000 description 4
- WRHNZXUGMMDILA-OWOJBTEDSA-N 1-[(e)-2-(4-fluorophenyl)ethenyl]-4-nitrobenzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C1=CC=C(F)C=C1 WRHNZXUGMMDILA-OWOJBTEDSA-N 0.000 description 4
- YWVVPMMEWIOPAG-UHFFFAOYSA-N 1-[2,5-difluoro-4-[(3-fluorophenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C(=C1)F)=CC(F)=C1OCC1=CC=CC(F)=C1 YWVVPMMEWIOPAG-UHFFFAOYSA-N 0.000 description 4
- DOHXHWDJEWJYTI-SNAWJCMRSA-N 1-fluoro-3-[(e)-2-(4-nitrophenyl)ethenyl]benzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C1=CC=CC(F)=C1 DOHXHWDJEWJYTI-SNAWJCMRSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- FUKHOQPXEPBRFC-NSCUHMNNSA-N 4-[(e)-2-(4-methoxyphenyl)ethenyl]aniline Chemical compound C1=CC(OC)=CC=C1\C=C\C1=CC=C(N)C=C1 FUKHOQPXEPBRFC-NSCUHMNNSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229910052718 tin Inorganic materials 0.000 description 4
- VHZVWBOBRRAWNR-LLVKDONJSA-N (3r)-1-[4-[(2,6-difluorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1C[C@@H](C(=O)O)CN1C(C=C1)=CC=C1OCC1=C(F)C=CC=C1F VHZVWBOBRRAWNR-LLVKDONJSA-N 0.000 description 3
- JQPRMUHZNWHVCP-CYBMUJFWSA-N (3r)-1-[4-[(3-chlorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1C[C@@H](C(=O)O)CN1C(C=C1)=CC=C1OCC1=CC=CC(Cl)=C1 JQPRMUHZNWHVCP-CYBMUJFWSA-N 0.000 description 3
- MXSCXPANVAFQFT-CQSZACIVSA-N (3r)-1-[4-[(3-chlorophenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1C[C@@H](C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=CC(Cl)=C1 MXSCXPANVAFQFT-CQSZACIVSA-N 0.000 description 3
- VHGRUQDIDUZEAI-CYBMUJFWSA-N (3r)-1-[4-[(4-fluorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1C[C@@H](C(=O)O)CN1C(C=C1)=CC=C1OCC1=CC=C(F)C=C1 VHGRUQDIDUZEAI-CYBMUJFWSA-N 0.000 description 3
- FOFWGZVXIPFALH-SNVBAGLBSA-N (3r)-5-oxo-1-[4-[(2,4,6-trifluorophenyl)methoxy]phenyl]pyrrolidine-3-carboxylic acid Chemical compound O=C1C[C@@H](C(=O)O)CN1C(C=C1)=CC=C1OCC1=C(F)C=C(F)C=C1F FOFWGZVXIPFALH-SNVBAGLBSA-N 0.000 description 3
- LXVAJBHGISGUBF-LLVKDONJSA-N (3r)-n-methyl-5-oxo-1-[4-[(2,4,6-trifluorophenyl)methoxy]phenyl]pyrrolidine-3-carboxamide Chemical compound O=C1C[C@@H](C(=O)NC)CN1C(C=C1)=CC=C1OCC1=C(F)C=C(F)C=C1F LXVAJBHGISGUBF-LLVKDONJSA-N 0.000 description 3
- PDFBJCRLHMEJQP-NSCUHMNNSA-N (E)-1-Methoxy-4-[2-(4-nitrophenyl)ethenyl]benzene Chemical compound C1=CC(OC)=CC=C1\C=C\C1=CC=C([N+]([O-])=O)C=C1 PDFBJCRLHMEJQP-NSCUHMNNSA-N 0.000 description 3
- WAPNOHKVXSQRPX-SSDOTTSWSA-N (R)-1-phenylethanol Chemical compound C[C@@H](O)C1=CC=CC=C1 WAPNOHKVXSQRPX-SSDOTTSWSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- HURFPEPYYXAAPA-UHFFFAOYSA-N 1,4-difluoro-2-[(3-fluorophenyl)methoxy]-5-nitrobenzene Chemical compound C1=C(F)C([N+](=O)[O-])=CC(F)=C1OCC1=CC=CC(F)=C1 HURFPEPYYXAAPA-UHFFFAOYSA-N 0.000 description 3
- WKGWMIAHCAJHPK-OWOJBTEDSA-N 1-[(e)-2-(4-chlorophenyl)ethenyl]-4-nitrobenzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C1=CC=C(Cl)C=C1 WKGWMIAHCAJHPK-OWOJBTEDSA-N 0.000 description 3
- BPPVTZMIBJABDB-UHFFFAOYSA-N 1-[2,5-difluoro-4-[(3-fluorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1CC(C(=O)O)CN1C(C(=C1)F)=CC(F)=C1OCC1=CC=CC(F)=C1 BPPVTZMIBJABDB-UHFFFAOYSA-N 0.000 description 3
- RUJXEUUQFZVPDT-UHFFFAOYSA-N 1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1CC(C(=O)O)CN1C(C=C1)=CC=C1OCC1=CC=CC(F)=C1 RUJXEUUQFZVPDT-UHFFFAOYSA-N 0.000 description 3
- BCLJGCSEIXNITA-UHFFFAOYSA-N 1-[4-[(4-fluorophenyl)methoxy]-3-methylphenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1C)=CC=C1OCC1=CC=C(F)C=C1 BCLJGCSEIXNITA-UHFFFAOYSA-N 0.000 description 3
- MYHOISPDNLSJPT-UHFFFAOYSA-N 1-[4-[(5-fluoro-2-methylphenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC(F)=CC=C1C MYHOISPDNLSJPT-UHFFFAOYSA-N 0.000 description 3
- XAKAFXVSEOHHIV-SNAWJCMRSA-N 1-[4-[(e)-2-(3-fluorophenyl)ethenyl]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1CC(C(=O)O)CN1C(C=C1)=CC=C1\C=C\C1=CC=CC(F)=C1 XAKAFXVSEOHHIV-SNAWJCMRSA-N 0.000 description 3
- XTIDPFXTFJYGQB-AATRIKPKSA-N 1-[4-[(e)-2-(3-fluorophenyl)ethenyl]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1\C=C\C1=CC=CC(F)=C1 XTIDPFXTFJYGQB-AATRIKPKSA-N 0.000 description 3
- DAVNSUPLOVZQDJ-AATRIKPKSA-N 1-[4-[(e)-2-(3-methoxyphenyl)ethenyl]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound COC1=CC=CC(\C=C\C=2C=CC(=CC=2)N2C(CC(C2)C(O)=O)=O)=C1 DAVNSUPLOVZQDJ-AATRIKPKSA-N 0.000 description 3
- UNHWEUHVSJCITG-OWOJBTEDSA-N 1-[4-[(e)-2-(4-fluorophenyl)ethenyl]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1CC(C(=O)O)CN1C(C=C1)=CC=C1\C=C\C1=CC=C(F)C=C1 UNHWEUHVSJCITG-OWOJBTEDSA-N 0.000 description 3
- NXIXZMHUDUBWQT-NSCUHMNNSA-N 1-[4-[(e)-2-(4-fluorophenyl)ethenyl]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1\C=C\C1=CC=C(F)C=C1 NXIXZMHUDUBWQT-NSCUHMNNSA-N 0.000 description 3
- MMCOURKTXCYMTR-NSCUHMNNSA-N 1-[4-[(e)-2-(4-methoxyphenyl)ethenyl]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound C1=CC(OC)=CC=C1\C=C\C1=CC=C(N2C(CC(C2)C(O)=O)=O)C=C1 MMCOURKTXCYMTR-NSCUHMNNSA-N 0.000 description 3
- MIYCTBPUOJAOEY-UHFFFAOYSA-N 1-[4-[2-(3-chlorophenyl)ethyl]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1CC(C(=O)O)CN1C(C=C1)=CC=C1CCC1=CC=CC(Cl)=C1 MIYCTBPUOJAOEY-UHFFFAOYSA-N 0.000 description 3
- YYRYRFKGJOBOPH-UHFFFAOYSA-N 1-[4-[2-(3-chlorophenyl)ethyl]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1CCC1=CC=CC(Cl)=C1 YYRYRFKGJOBOPH-UHFFFAOYSA-N 0.000 description 3
- URPRHYAMVWSMGD-UHFFFAOYSA-N 1-[4-[2-(3-fluorophenyl)ethyl]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1CC(C(=O)O)CN1C(C=C1)=CC=C1CCC1=CC=CC(F)=C1 URPRHYAMVWSMGD-UHFFFAOYSA-N 0.000 description 3
- XLVBYWVJERXSEM-UHFFFAOYSA-N 1-[4-[2-(3-methoxyphenyl)ethyl]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound COC1=CC=CC(CCC=2C=CC(=CC=2)N2C(CC(C2)C(O)=O)=O)=C1 XLVBYWVJERXSEM-UHFFFAOYSA-N 0.000 description 3
- LZVDLIHLAONUJT-UHFFFAOYSA-N 1-[4-[2-(4-chlorophenyl)ethyl]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1CC(C(=O)O)CN1C(C=C1)=CC=C1CCC1=CC=C(Cl)C=C1 LZVDLIHLAONUJT-UHFFFAOYSA-N 0.000 description 3
- KRRYNWHBQHWNHX-UHFFFAOYSA-N 1-[4-[2-(4-fluorophenyl)ethyl]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1CC(C(=O)O)CN1C(C=C1)=CC=C1CCC1=CC=C(F)C=C1 KRRYNWHBQHWNHX-UHFFFAOYSA-N 0.000 description 3
- PNIXPLYGGKTMBO-UHFFFAOYSA-N 1-[6-[(4-fluorophenyl)methoxy]pyridin-3-yl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1CC(C(=O)O)CN1C(C=N1)=CC=C1OCC1=CC=C(F)C=C1 PNIXPLYGGKTMBO-UHFFFAOYSA-N 0.000 description 3
- REQIUGALNFLDSJ-SNAWJCMRSA-N 1-chloro-3-[(e)-2-(4-nitrophenyl)ethenyl]benzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C1=CC=CC(Cl)=C1 REQIUGALNFLDSJ-SNAWJCMRSA-N 0.000 description 3
- ZKWGCQHPGYOCSV-AATRIKPKSA-N 1-methoxy-3-[(e)-2-(4-nitrophenyl)ethenyl]benzene Chemical compound COC1=CC=CC(\C=C\C=2C=CC(=CC=2)[N+]([O-])=O)=C1 ZKWGCQHPGYOCSV-AATRIKPKSA-N 0.000 description 3
- DMELCBLCVSRXIM-UHFFFAOYSA-N 2,5-difluoro-4-[(3-fluorophenyl)methoxy]aniline Chemical compound C1=C(F)C(N)=CC(F)=C1OCC1=CC=CC(F)=C1 DMELCBLCVSRXIM-UHFFFAOYSA-N 0.000 description 3
- VISJDLKTEXTLFN-UHFFFAOYSA-N 2-[(4-fluorophenyl)methoxy]-5-nitropyridine Chemical compound N1=CC([N+](=O)[O-])=CC=C1OCC1=CC=C(F)C=C1 VISJDLKTEXTLFN-UHFFFAOYSA-N 0.000 description 3
- KEAKHFXYOLNMHI-SNAWJCMRSA-N 4-[(e)-2-(3-fluorophenyl)ethenyl]aniline Chemical compound C1=CC(N)=CC=C1\C=C\C1=CC=CC(F)=C1 KEAKHFXYOLNMHI-SNAWJCMRSA-N 0.000 description 3
- AAVIHGPUAGOTOM-OWOJBTEDSA-N 4-[(e)-2-(4-fluorophenyl)ethenyl]aniline Chemical compound C1=CC(N)=CC=C1\C=C\C1=CC=C(F)C=C1 AAVIHGPUAGOTOM-OWOJBTEDSA-N 0.000 description 3
- HEFZPZLMEWXHHH-UHFFFAOYSA-N 4-[2-(3-chlorophenyl)ethyl]aniline Chemical compound C1=CC(N)=CC=C1CCC1=CC=CC(Cl)=C1 HEFZPZLMEWXHHH-UHFFFAOYSA-N 0.000 description 3
- OZPIDARUDRKJOF-UHFFFAOYSA-N 4-[2-(3-fluorophenyl)ethyl]aniline Chemical compound C1=CC(N)=CC=C1CCC1=CC=CC(F)=C1 OZPIDARUDRKJOF-UHFFFAOYSA-N 0.000 description 3
- KVOIZIWCFFTRTE-UHFFFAOYSA-N 4-[2-(3-methoxyphenyl)ethyl]aniline Chemical compound COC1=CC=CC(CCC=2C=CC(N)=CC=2)=C1 KVOIZIWCFFTRTE-UHFFFAOYSA-N 0.000 description 3
- UYYBSDJRXMMCAA-UHFFFAOYSA-N 4-[2-(4-chlorophenyl)ethyl]aniline Chemical compound C1=CC(N)=CC=C1CCC1=CC=C(Cl)C=C1 UYYBSDJRXMMCAA-UHFFFAOYSA-N 0.000 description 3
- WXLZJFFGXPLTEZ-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)ethyl]aniline Chemical compound C1=CC(N)=CC=C1CCC1=CC=C(F)C=C1 WXLZJFFGXPLTEZ-UHFFFAOYSA-N 0.000 description 3
- CARHTDHRIJKRTM-UHFFFAOYSA-N 6-[(4-fluorophenyl)methoxy]pyridin-3-amine Chemical compound N1=CC(N)=CC=C1OCC1=CC=C(F)C=C1 CARHTDHRIJKRTM-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- CMDGKCLLYSCKOE-GFCCVEGCSA-N methyl (3r)-1-[4-[(2,6-difluorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1C[C@@H](C(=O)OC)CN1C(C=C1)=CC=C1OCC1=C(F)C=CC=C1F CMDGKCLLYSCKOE-GFCCVEGCSA-N 0.000 description 3
- VCOOLPNKUDKQIA-CQSZACIVSA-N methyl (3r)-1-[4-[(3-chlorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1C[C@@H](C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC=CC(Cl)=C1 VCOOLPNKUDKQIA-CQSZACIVSA-N 0.000 description 3
- UBUBLQQZNPQHBG-CQSZACIVSA-N methyl (3r)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1C[C@@H](C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC=CC(F)=C1 UBUBLQQZNPQHBG-CQSZACIVSA-N 0.000 description 3
- UMNKNALFOGMEPY-UHFFFAOYSA-N methyl 1-(4-hydroxy-3-methylphenyl)-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C1=CC=C(O)C(C)=C1 UMNKNALFOGMEPY-UHFFFAOYSA-N 0.000 description 3
- PECUBSMQWCZBKU-UHFFFAOYSA-N methyl 1-[4-[(3-fluorophenyl)methoxy]-3-methylphenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1C)=CC=C1OCC1=CC=CC(F)=C1 PECUBSMQWCZBKU-UHFFFAOYSA-N 0.000 description 3
- YXJBUQFCUOTSQE-UHFFFAOYSA-N methyl 1-[4-[(4-fluorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC=C(F)C=C1 YXJBUQFCUOTSQE-UHFFFAOYSA-N 0.000 description 3
- UKRWOZFFRXEAMQ-VOTSOKGWSA-N methyl 1-[4-[(e)-2-(3-methoxyphenyl)ethenyl]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1\C=C\C1=CC=CC(OC)=C1 UKRWOZFFRXEAMQ-VOTSOKGWSA-N 0.000 description 3
- GGGQJTBGSSIFBV-ONEGZZNKSA-N methyl 1-[4-[(e)-2-(4-methoxyphenyl)ethenyl]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1\C=C\C1=CC=C(OC)C=C1 GGGQJTBGSSIFBV-ONEGZZNKSA-N 0.000 description 3
- SLYALWDSVQAFGG-UHFFFAOYSA-N methyl 1-[4-[2-(3-chlorophenyl)ethyl]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1CCC1=CC=CC(Cl)=C1 SLYALWDSVQAFGG-UHFFFAOYSA-N 0.000 description 3
- JGPVPFPSFQVCDM-UHFFFAOYSA-N methyl 1-[4-[2-(3-methoxyphenyl)ethyl]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1CCC1=CC=CC(OC)=C1 JGPVPFPSFQVCDM-UHFFFAOYSA-N 0.000 description 3
- TZGHCYTUWOHYDZ-UHFFFAOYSA-N methyl 1-[4-[2-(4-chlorophenyl)ethyl]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1CCC1=CC=C(Cl)C=C1 TZGHCYTUWOHYDZ-UHFFFAOYSA-N 0.000 description 3
- XHZXOHVMORMWGM-UHFFFAOYSA-N methyl 1-[4-[2-(4-fluorophenyl)ethyl]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1CCC1=CC=C(F)C=C1 XHZXOHVMORMWGM-UHFFFAOYSA-N 0.000 description 3
- SOFWFRXMBUNDSP-UHFFFAOYSA-N methyl 5-oxo-1-(4-phenylmethoxyphenyl)pyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC=CC=C1 SOFWFRXMBUNDSP-UHFFFAOYSA-N 0.000 description 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 3
- AYMPWHXDEUIFJM-UHFFFAOYSA-N n-methyl-5-oxo-1-[4-[(2,3,6-trifluorophenyl)methoxy]phenyl]pyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=C(F)C=CC(F)=C1F AYMPWHXDEUIFJM-UHFFFAOYSA-N 0.000 description 3
- NRZNZPHMVNSFCO-UHFFFAOYSA-N n-methyl-5-oxo-1-[4-[(2,4,5-trifluorophenyl)methoxy]phenyl]pyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC(F)=C(F)C=C1F NRZNZPHMVNSFCO-UHFFFAOYSA-N 0.000 description 3
- GOMARTFRYVPQIN-UHFFFAOYSA-N n-methyl-5-oxo-1-[4-[[3-(trifluoromethoxy)phenyl]methoxy]phenyl]pyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=CC(OC(F)(F)F)=C1 GOMARTFRYVPQIN-UHFFFAOYSA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 125000005490 tosylate group Chemical class 0.000 description 3
- 150000008648 triflates Chemical class 0.000 description 3
- 229960003732 tyramine Drugs 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- GEZMEIHVFSWOCA-UHFFFAOYSA-N (4-fluorophenyl)methanol Chemical compound OCC1=CC=C(F)C=C1 GEZMEIHVFSWOCA-UHFFFAOYSA-N 0.000 description 2
- SPKQNDHHJGYPJV-UHFFFAOYSA-N 1-(4-hydroperoxyphenyl)-5-oxopyrrolidine-3-carboxylic acid Chemical compound C1=CC(OO)=CC=C1N1C(=O)CC(C(O)=O)C1 SPKQNDHHJGYPJV-UHFFFAOYSA-N 0.000 description 2
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 2
- XKYMGEGSUAZGMQ-UHFFFAOYSA-N 1-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1CC(C(=O)O)CN1C(C=C1F)=CC=C1OCC1=CC=CC(F)=C1 XKYMGEGSUAZGMQ-UHFFFAOYSA-N 0.000 description 2
- QJACINXXWHDNAN-UHFFFAOYSA-N 1-[4-[(3,4-difluorophenyl)methoxy]phenyl]-4-(hydroxymethyl)pyrrolidin-2-one Chemical compound O=C1CC(CO)CN1C(C=C1)=CC=C1OCC1=CC=C(F)C(F)=C1 QJACINXXWHDNAN-UHFFFAOYSA-N 0.000 description 2
- ITKKKCABYOGEED-UHFFFAOYSA-N 1-[4-[(3-fluorophenyl)methoxy]phenyl]-4-(hydroxymethyl)pyrrolidin-2-one Chemical compound O=C1CC(CO)CN1C(C=C1)=CC=C1OCC1=CC=CC(F)=C1 ITKKKCABYOGEED-UHFFFAOYSA-N 0.000 description 2
- HXRHHIADVPTANH-UHFFFAOYSA-N 1-[4-[(4-fluorophenyl)methoxy]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1OCC1=CC=C(F)C=C1 HXRHHIADVPTANH-UHFFFAOYSA-N 0.000 description 2
- DDGRAFHHXYIQQR-UHFFFAOYSA-N 1-chloro-3-(chloromethyl)benzene Chemical compound ClCC1=CC=CC(Cl)=C1 DDGRAFHHXYIQQR-UHFFFAOYSA-N 0.000 description 2
- SPPLWANVCVTGEQ-UHFFFAOYSA-N 2-(bromomethyl)-1,3,5-trifluorobenzene Chemical compound FC1=CC(F)=C(CBr)C(F)=C1 SPPLWANVCVTGEQ-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- MXXJUUMBABMIDY-UHFFFAOYSA-N 2-fluoro-1-[(3-fluorophenyl)methoxy]-4-nitrobenzene Chemical compound FC1=CC([N+](=O)[O-])=CC=C1OCC1=CC=CC(F)=C1 MXXJUUMBABMIDY-UHFFFAOYSA-N 0.000 description 2
- HKFSTUBEKQHSNR-UHFFFAOYSA-N 2-fluoro-4-[(3-fluorophenyl)methoxy]-1-nitrobenzene Chemical compound C1=C(F)C([N+](=O)[O-])=CC=C1OCC1=CC=CC(F)=C1 HKFSTUBEKQHSNR-UHFFFAOYSA-N 0.000 description 2
- RDQGBLUJJHDIOR-UHFFFAOYSA-N 2-fluoro-4-[(3-fluorophenyl)methoxy]aniline Chemical compound C1=C(F)C(N)=CC=C1OCC1=CC=CC(F)=C1 RDQGBLUJJHDIOR-UHFFFAOYSA-N 0.000 description 2
- USOZORKORACUMN-UHFFFAOYSA-N 3-fluoro-4-[(3-fluorophenyl)methoxy]aniline Chemical compound FC1=CC(N)=CC=C1OCC1=CC=CC(F)=C1 USOZORKORACUMN-UHFFFAOYSA-N 0.000 description 2
- QDHRSLFSDGCJFX-UHFFFAOYSA-N 3-fluorobenzyl alcohol Chemical compound OCC1=CC=CC(F)=C1 QDHRSLFSDGCJFX-UHFFFAOYSA-N 0.000 description 2
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 2
- HQVYTFZGXVLUOI-UHFFFAOYSA-N 4-(chloromethyl)-1-(4-phenylmethoxyphenyl)pyrrolidin-2-one Chemical compound O=C1CC(CCl)CN1C(C=C1)=CC=C1OCC1=CC=CC=C1 HQVYTFZGXVLUOI-UHFFFAOYSA-N 0.000 description 2
- XCPPOMFQMGXNTO-UHFFFAOYSA-N 4-(hydroxymethyl)-1-(4-phenylmethoxyphenyl)pyrrolidin-2-one Chemical compound O=C1CC(CO)CN1C(C=C1)=CC=C1OCC1=CC=CC=C1 XCPPOMFQMGXNTO-UHFFFAOYSA-N 0.000 description 2
- KQIPLUOUWQXDOT-AATRIKPKSA-N 4-[(e)-2-(3-methoxyphenyl)ethenyl]aniline Chemical compound COC1=CC=CC(\C=C\C=2C=CC(N)=CC=2)=C1 KQIPLUOUWQXDOT-AATRIKPKSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical class OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000006959 Williamson synthesis reaction Methods 0.000 description 2
- 241000179532 [Candida] cylindracea Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- YXJBUQFCUOTSQE-CQSZACIVSA-N methyl (3r)-1-[4-[(4-fluorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1C[C@@H](C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC=C(F)C=C1 YXJBUQFCUOTSQE-CQSZACIVSA-N 0.000 description 2
- IHVWIDOFPBLQOG-LLVKDONJSA-N methyl (3r)-5-oxo-1-[4-[(2,4,6-trifluorophenyl)methoxy]phenyl]pyrrolidine-3-carboxylate Chemical compound O=C1C[C@@H](C(=O)OC)CN1C(C=C1)=CC=C1OCC1=C(F)C=C(F)C=C1F IHVWIDOFPBLQOG-LLVKDONJSA-N 0.000 description 2
- YDYAZXZGWDLWCQ-UHFFFAOYSA-N methyl 1-(4-hydroperoxyphenyl)-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C1=CC=C(OO)C=C1 YDYAZXZGWDLWCQ-UHFFFAOYSA-N 0.000 description 2
- NSJCVURUQHUPIV-NSCUHMNNSA-N methyl 1-[4-[(e)-2-(4-fluorophenyl)ethenyl]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1\C=C\C1=CC=C(F)C=C1 NSJCVURUQHUPIV-NSCUHMNNSA-N 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- 239000012768 molten material Substances 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 238000007833 oxidative deamination reaction Methods 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 150000003003 phosphines Chemical class 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical group CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229940075966 (+)- menthol Drugs 0.000 description 1
- NOOLISFMXDJSKH-AEJSXWLSSA-N (+)-menthol Chemical compound CC(C)[C@H]1CC[C@H](C)C[C@@H]1O NOOLISFMXDJSKH-AEJSXWLSSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- YJQDVBPZXNALEE-UHFFFAOYSA-N (2,4,6-trifluorophenyl)methanol Chemical compound OCC1=C(F)C=C(F)C=C1F YJQDVBPZXNALEE-UHFFFAOYSA-N 0.000 description 1
- LVICICZQETYOGS-UHFFFAOYSA-N (2,6-difluorophenyl)methanol Chemical compound OCC1=C(F)C=CC=C1F LVICICZQETYOGS-UHFFFAOYSA-N 0.000 description 1
- BTANRVKWQNVYAZ-SCSAIBSYSA-N (2R)-butan-2-ol Chemical compound CC[C@@H](C)O BTANRVKWQNVYAZ-SCSAIBSYSA-N 0.000 description 1
- BTANRVKWQNVYAZ-BYPYZUCNSA-N (2S)-butan-2-ol Chemical compound CC[C@H](C)O BTANRVKWQNVYAZ-BYPYZUCNSA-N 0.000 description 1
- ZSRDNPVYGSFUMD-UHFFFAOYSA-N (3-chlorophenyl)methanol Chemical compound OCC1=CC=CC(Cl)=C1 ZSRDNPVYGSFUMD-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- QHGUCRYDKWKLMG-QMMMGPOBSA-N (R)-octopamine Chemical compound NC[C@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-QMMMGPOBSA-N 0.000 description 1
- ROJNMGYMBLNTPK-UHFFFAOYSA-N 1,2,4-trifluoro-5-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=C(F)C=C1F ROJNMGYMBLNTPK-UHFFFAOYSA-N 0.000 description 1
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 1
- DGSXDQVPGXFOAN-UHFFFAOYSA-N 1-(bromomethyl)-2,3,4-trifluorobenzene Chemical compound FC1=CC=C(CBr)C(F)=C1F DGSXDQVPGXFOAN-UHFFFAOYSA-N 0.000 description 1
- GAUXEYCSWSMMFZ-UHFFFAOYSA-N 1-(bromomethyl)-2,4,5-trifluorobenzene Chemical compound FC1=CC(F)=C(CBr)C=C1F GAUXEYCSWSMMFZ-UHFFFAOYSA-N 0.000 description 1
- WAUNFWSVXRPCDQ-UHFFFAOYSA-N 1-(bromomethyl)-2-methoxybenzene Chemical compound COC1=CC=CC=C1CBr WAUNFWSVXRPCDQ-UHFFFAOYSA-N 0.000 description 1
- QSIVWRRHVXSDNE-UHFFFAOYSA-N 1-(bromomethyl)-3-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=CC(CBr)=C1 QSIVWRRHVXSDNE-UHFFFAOYSA-N 0.000 description 1
- ZKSOJQDNSNJIQW-UHFFFAOYSA-N 1-(bromomethyl)-3-methoxybenzene Chemical compound COC1=CC=CC(CBr)=C1 ZKSOJQDNSNJIQW-UHFFFAOYSA-N 0.000 description 1
- XGASTRVQNVVYIZ-UHFFFAOYSA-N 1-(chloromethyl)-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(CCl)=C1 XGASTRVQNVVYIZ-UHFFFAOYSA-N 0.000 description 1
- XOVVTVHKXDVNPX-UHFFFAOYSA-N 1-[2-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1CC(C(=O)O)CN1C(C(=C1)F)=CC=C1OCC1=CC=CC(F)=C1 XOVVTVHKXDVNPX-UHFFFAOYSA-N 0.000 description 1
- YQWIBADSRLKTPR-AATRIKPKSA-N 1-[4-[(e)-2-(3-chlorophenyl)ethenyl]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1\C=C\C1=CC=CC(Cl)=C1 YQWIBADSRLKTPR-AATRIKPKSA-N 0.000 description 1
- PCNHSKOPIWNJFH-NSCUHMNNSA-N 1-[4-[(e)-2-(4-chlorophenyl)ethenyl]phenyl]-n-methyl-5-oxopyrrolidine-3-carboxamide Chemical compound O=C1CC(C(=O)NC)CN1C(C=C1)=CC=C1\C=C\C1=CC=C(Cl)C=C1 PCNHSKOPIWNJFH-NSCUHMNNSA-N 0.000 description 1
- LEDLKMLJORECFW-UHFFFAOYSA-N 1-fluoro-2,4-bis[(3-fluorophenyl)methoxy]-5-nitrobenzene Chemical compound C1=C(OCC=2C=C(F)C=CC=2)C([N+](=O)[O-])=CC(F)=C1OCC1=CC=CC(F)=C1 LEDLKMLJORECFW-UHFFFAOYSA-N 0.000 description 1
- WAPNOHKVXSQRPX-UHFFFAOYSA-N 1-phenylethanol Chemical compound CC(O)C1=CC=CC=C1 WAPNOHKVXSQRPX-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- XGLVDUUYFKXKPL-UHFFFAOYSA-N 2-(2-methoxyethoxy)-n,n-bis[2-(2-methoxyethoxy)ethyl]ethanamine Chemical compound COCCOCCN(CCOCCOC)CCOCCOC XGLVDUUYFKXKPL-UHFFFAOYSA-N 0.000 description 1
- JPBWEVKHPSNBCE-UHFFFAOYSA-N 2-(bromomethyl)-1,3,4-trifluorobenzene Chemical compound FC1=CC=C(F)C(CBr)=C1F JPBWEVKHPSNBCE-UHFFFAOYSA-N 0.000 description 1
- LSXJPJGBWSZHTM-UHFFFAOYSA-N 2-(bromomethyl)-1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1CBr LSXJPJGBWSZHTM-UHFFFAOYSA-N 0.000 description 1
- DRIYGEORZARQGO-UHFFFAOYSA-N 2-(bromomethyl)-4-fluoro-1-methylbenzene Chemical compound CC1=CC=C(F)C=C1CBr DRIYGEORZARQGO-UHFFFAOYSA-N 0.000 description 1
- BAZVFQBTJPBRTJ-UHFFFAOYSA-N 2-chloro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1 BAZVFQBTJPBRTJ-UHFFFAOYSA-N 0.000 description 1
- RUJHATQMIMUYKD-UHFFFAOYSA-N 2-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C(CCN)=CC=CC2=C1 RUJHATQMIMUYKD-UHFFFAOYSA-N 0.000 description 1
- CVKOOKPNCVYHNY-UHFFFAOYSA-N 3-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC(C#N)=C1 CVKOOKPNCVYHNY-UHFFFAOYSA-N 0.000 description 1
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
- CSSGKHVRDGATJL-UHFFFAOYSA-N 3-fluoro-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C(F)=C1 CSSGKHVRDGATJL-UHFFFAOYSA-N 0.000 description 1
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 1
- JJIFTOPVKWDHJI-UHFFFAOYSA-N 4-(bromomethyl)-1,2-difluorobenzene Chemical compound FC1=CC=C(CBr)C=C1F JJIFTOPVKWDHJI-UHFFFAOYSA-N 0.000 description 1
- HDGMAACKJSBLMW-UHFFFAOYSA-N 4-amino-2-methylphenol Chemical compound CC1=CC(N)=CC=C1O HDGMAACKJSBLMW-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- FIIDVVUUWRJXLF-UHFFFAOYSA-N 4-phenylmethoxyaniline Chemical compound C1=CC(N)=CC=C1OCC1=CC=CC=C1 FIIDVVUUWRJXLF-UHFFFAOYSA-N 0.000 description 1
- ORPHLVJBJOCHBR-UHFFFAOYSA-N 403-19-0 Chemical compound OC1=CC=C([N+]([O-])=O)C=C1F ORPHLVJBJOCHBR-UHFFFAOYSA-N 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- FOFWGZVXIPFALH-UHFFFAOYSA-N 5-oxo-1-[4-[(2,4,6-trifluorophenyl)methoxy]phenyl]pyrrolidine-3-carboxylic acid Chemical compound O=C1CC(C(=O)O)CN1C(C=C1)=CC=C1OCC1=C(F)C=C(F)C=C1F FOFWGZVXIPFALH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100149678 Caenorhabditis elegans snr-3 gene Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000694718 Homo sapiens Amine oxidase [flavin-containing] A Proteins 0.000 description 1
- 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020802 Hypertensive crisis Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- QHGUCRYDKWKLMG-MRVPVSSYSA-N Octopamine Natural products NC[C@@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-MRVPVSSYSA-N 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 238000000441 X-ray spectroscopy Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 125000003354 benzotriazolyl group Chemical class N1N=NC2=C1C=CC=C2* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- BTFHLQRNAMSNLC-UHFFFAOYSA-N clorgyline Chemical compound C#CCN(C)CCCOC1=CC=C(Cl)C=C1Cl BTFHLQRNAMSNLC-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- CMDGKCLLYSCKOE-UHFFFAOYSA-N methyl 1-[4-[(2,6-difluorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=C(F)C=CC=C1F CMDGKCLLYSCKOE-UHFFFAOYSA-N 0.000 description 1
- OOAVGYTUPDSJSM-UHFFFAOYSA-N methyl 1-[4-[(2-methoxyphenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC=CC=C1OC OOAVGYTUPDSJSM-UHFFFAOYSA-N 0.000 description 1
- POZBJFFDFWVRKW-UHFFFAOYSA-N methyl 1-[4-[(3,4-difluorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC=C(F)C(F)=C1 POZBJFFDFWVRKW-UHFFFAOYSA-N 0.000 description 1
- GQUSHEBYCIGFMM-UHFFFAOYSA-N methyl 1-[4-[(3-chlorophenyl)methoxy]-3-methylphenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1C)=CC=C1OCC1=CC=CC(Cl)=C1 GQUSHEBYCIGFMM-UHFFFAOYSA-N 0.000 description 1
- VCOOLPNKUDKQIA-UHFFFAOYSA-N methyl 1-[4-[(3-chlorophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC=CC(Cl)=C1 VCOOLPNKUDKQIA-UHFFFAOYSA-N 0.000 description 1
- UDIUXZPGURDCCK-UHFFFAOYSA-N methyl 1-[4-[(3-cyanophenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC=CC(C#N)=C1 UDIUXZPGURDCCK-UHFFFAOYSA-N 0.000 description 1
- MUIDZXAZZUFYAS-UHFFFAOYSA-N methyl 1-[4-[(3-methoxyphenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC=CC(OC)=C1 MUIDZXAZZUFYAS-UHFFFAOYSA-N 0.000 description 1
- DHLVXDIORHEGFH-UHFFFAOYSA-N methyl 1-[4-[(4-fluorophenyl)methoxy]-3-methylphenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1C)=CC=C1OCC1=CC=C(F)C=C1 DHLVXDIORHEGFH-UHFFFAOYSA-N 0.000 description 1
- INLFDBPEDAZEKK-UHFFFAOYSA-N methyl 1-[4-[(5-fluoro-2-methylphenyl)methoxy]phenyl]-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC(F)=CC=C1C INLFDBPEDAZEKK-UHFFFAOYSA-N 0.000 description 1
- BFDDWABERUPPIN-UHFFFAOYSA-N methyl 2-oxopyrrolidine-3-carboxylate Chemical compound COC(=O)C1CCNC1=O BFDDWABERUPPIN-UHFFFAOYSA-N 0.000 description 1
- YUBLGNIUZATOHL-UHFFFAOYSA-N methyl 5-oxo-1-[4-[(2,3,4-trifluorophenyl)methoxy]phenyl]pyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC=C(F)C(F)=C1F YUBLGNIUZATOHL-UHFFFAOYSA-N 0.000 description 1
- NWFPCGLWXCEKDD-UHFFFAOYSA-N methyl 5-oxo-1-[4-[(2,3,6-trifluorophenyl)methoxy]phenyl]pyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=C(F)C=CC(F)=C1F NWFPCGLWXCEKDD-UHFFFAOYSA-N 0.000 description 1
- CQVZSRHKROYCPG-UHFFFAOYSA-N methyl 5-oxo-1-[4-[(2,4,5-trifluorophenyl)methoxy]phenyl]pyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC(F)=C(F)C=C1F CQVZSRHKROYCPG-UHFFFAOYSA-N 0.000 description 1
- IHVWIDOFPBLQOG-UHFFFAOYSA-N methyl 5-oxo-1-[4-[(2,4,6-trifluorophenyl)methoxy]phenyl]pyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=C(F)C=C(F)C=C1F IHVWIDOFPBLQOG-UHFFFAOYSA-N 0.000 description 1
- FMQQLOLTTKSHMW-UHFFFAOYSA-N methyl 5-oxo-1-[4-[(3,4,5-trifluorophenyl)methoxy]phenyl]pyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC(F)=C(F)C(F)=C1 FMQQLOLTTKSHMW-UHFFFAOYSA-N 0.000 description 1
- YRNSDNSRNFMTDC-UHFFFAOYSA-N methyl 5-oxo-1-[4-[[3-(trifluoromethoxy)phenyl]methoxy]phenyl]pyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC=CC(OC(F)(F)F)=C1 YRNSDNSRNFMTDC-UHFFFAOYSA-N 0.000 description 1
- KQPXVUYQMYIVJA-UHFFFAOYSA-N methyl 5-oxo-1-[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]pyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1C(C=C1)=CC=C1OCC1=CC=CC(C(F)(F)F)=C1 KQPXVUYQMYIVJA-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960001576 octopamine Drugs 0.000 description 1
- 238000006772 olefination reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical group C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02021319 | 2002-09-20 | ||
| PCT/EP2003/010384 WO2004026827A1 (en) | 2002-09-20 | 2003-09-18 | Pyrrolidone derivatives as maob inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20050665L NO20050665L (no) | 2005-04-18 |
| NO330012B1 true NO330012B1 (no) | 2011-02-07 |
Family
ID=32010924
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050652A NO329754B1 (no) | 2002-09-20 | 2005-02-08 | Pyrrolidonderivater , farmasoytiske preparater inneholdende slike, slike forbindelserfor behandling av sykdommer samt anvendelse av medikamenter for behandling av skdom |
| NO20050665A NO330012B1 (no) | 2002-09-20 | 2005-02-08 | Pyrrolidonderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat inneholdende slike, slike forbindelser for behandling av sykdom samt anvendelse av slike for fremstilling av medikament for behandling av sykdom |
| NO20050701A NO20050701L (no) | 2002-09-20 | 2005-02-09 | 4-pyrrolidino-fenyl-benzyleter derivater |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050652A NO329754B1 (no) | 2002-09-20 | 2005-02-08 | Pyrrolidonderivater , farmasoytiske preparater inneholdende slike, slike forbindelserfor behandling av sykdommer samt anvendelse av medikamenter for behandling av skdom |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050701A NO20050701L (no) | 2002-09-20 | 2005-02-09 | 4-pyrrolidino-fenyl-benzyleter derivater |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US7235581B2 (es) |
| EP (3) | EP1542969B1 (es) |
| JP (3) | JP4335140B2 (es) |
| KR (3) | KR100676014B1 (es) |
| CN (3) | CN100503562C (es) |
| AR (3) | AR041299A1 (es) |
| AT (2) | ATE459601T1 (es) |
| AU (3) | AU2003267381B2 (es) |
| BR (4) | BR0314299A (es) |
| CA (3) | CA2498335A1 (es) |
| CY (1) | CY1110745T1 (es) |
| DE (2) | DE60331559D1 (es) |
| DK (1) | DK1542970T3 (es) |
| ES (2) | ES2338646T3 (es) |
| GT (3) | GT200300205A (es) |
| HK (3) | HK1083498A1 (es) |
| HR (3) | HRP20050261A2 (es) |
| JO (2) | JO2605B1 (es) |
| MX (3) | MXPA05002880A (es) |
| MY (3) | MY134480A (es) |
| NO (3) | NO329754B1 (es) |
| NZ (3) | NZ538048A (es) |
| PA (3) | PA8583001A1 (es) |
| PE (3) | PE20050077A1 (es) |
| PL (3) | PL376019A1 (es) |
| PT (1) | PT1542970E (es) |
| RU (3) | RU2323209C2 (es) |
| SI (1) | SI1542970T1 (es) |
| TW (3) | TWI286132B (es) |
| UY (3) | UY27991A1 (es) |
| WO (3) | WO2004026826A1 (es) |
| ZA (3) | ZA200501137B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8583001A1 (es) * | 2002-09-20 | 2004-04-23 | Hoffmann La Roche | Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b |
| GB0314373D0 (en) | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Chemical compounds |
| MX2007001169A (es) * | 2004-08-02 | 2007-03-12 | Hoffmann La Roche | Derivados de benciloxi como inhibidores de la oxidasa de monoamina b. |
| KR100845366B1 (ko) * | 2004-08-02 | 2008-07-09 | 에프. 호프만-라 로슈 아게 | 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체 |
| UA90708C2 (ru) | 2005-02-25 | 2010-05-25 | Ф. Хоффманн-Ля Рош Аг | Таблетки с улучшенной дисперсностью лекарственного вещества |
| DE602006003879D1 (de) * | 2005-03-15 | 2009-01-08 | Hoffmann La Roche | Verfahren zur herstellung von enantiomerenreinen 4-pyrrolidinophenyl- benzyletherderivaten |
| US7501528B2 (en) * | 2005-03-15 | 2009-03-10 | Hoffmann-La Roche Inc. | Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| TW200728258A (en) * | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| US7855218B2 (en) * | 2005-10-10 | 2010-12-21 | Convergence Pharmaceuticals Limited | Compounds |
| WO2008121407A1 (en) * | 2007-03-30 | 2008-10-09 | The Regents Of The University Of California | In vivo imaging of sulfotransferases |
| KR101220182B1 (ko) | 2009-02-25 | 2013-01-11 | 에스케이바이오팜 주식회사 | 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법 |
| CZ304053B6 (cs) * | 2011-08-22 | 2013-09-04 | Farmak, A. S. | Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu |
| KR102018284B1 (ko) * | 2013-02-28 | 2019-09-05 | 삼성디스플레이 주식회사 | 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치 |
| RU2661156C2 (ru) | 2013-03-14 | 2018-07-12 | Дарт Нейросайенс (Кайман) Лтд. | Замещенные нафтиридиновые и хинолиновые соединения как ингибиторы мао |
| CZ305213B6 (cs) | 2013-04-29 | 2015-06-10 | Farmak, A. S. | Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy |
| JP2016535046A (ja) * | 2013-10-29 | 2016-11-10 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | アルツハイマー病の処置に有用なピロリドン誘導体の結晶形及びその製造法 |
| ES2912881T3 (es) | 2014-12-23 | 2022-05-30 | Convergence Pharmaceuticals | Procedimiento para preparar derivados de alfa-carboxamida pirrolidina |
| CN107223052A (zh) * | 2015-03-27 | 2017-09-29 | 豪夫迈·罗氏有限公司 | 包含sembragiline的药物制剂 |
| JP7169592B2 (ja) | 2017-09-27 | 2022-11-11 | 国立大学法人 鹿児島大学 | Ｐａｃ１受容体拮抗薬を用いた鎮痛薬 |
| KR20200061381A (ko) | 2017-10-05 | 2020-06-02 | 바이오젠 인크. | 알파-카르복스아미드 피롤리딘 유도체를 제조하기 위한 공정 |
| CN108299272B (zh) * | 2018-01-31 | 2019-10-18 | 福州大学 | 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法 |
| CA3092747A1 (en) * | 2018-03-08 | 2019-09-12 | Sunshine Lake Pharma Co., Ltd. | Pyrrolidineamide derivatives and uses thereof |
| JPWO2020175134A1 (ja) | 2019-02-27 | 2021-12-23 | 国立大学法人 鹿児島大学 | Ｐａｃ１受容体拮抗薬を用いた鎮痒薬 |
| EP4147701A1 (en) | 2020-05-08 | 2023-03-15 | Kagoshima University | Antidepressant/anxiolytic drug in which pac1 receptor antagonist is used |
| CN112851561A (zh) * | 2021-01-29 | 2021-05-28 | 南京艾美斐生物医药科技有限公司 | 一种nr6a1蛋白受体抑制剂及其制备和应用 |
| WO2022268520A1 (de) | 2021-06-21 | 2022-12-29 | Bayer Aktiengesellschaft | Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4348393A (en) * | 1978-06-09 | 1982-09-07 | Delalande S.A. | N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones |
| FR2500831A1 (fr) | 1981-02-27 | 1982-09-03 | Delalande Sa | Nouvelles n-aryl-oxazolidinones et -pyrrolidinones |
| ES2087097T3 (es) | 1989-04-19 | 1996-07-16 | Otsuka Pharma Co Ltd | Derivados de acidos fenilcarboxilicos que contienen un heterociclo. |
| US5679715A (en) | 1995-06-07 | 1997-10-21 | Harris; Richard Y. | Method for treating multiple sclerosis |
| WO1997033572A1 (en) | 1996-03-15 | 1997-09-18 | Somerset Pharmaceuticals, Inc. | Method for preventing and treating peripheral neurophathy by administering selegiline |
| US5683404A (en) * | 1996-06-05 | 1997-11-04 | Metagen, Llc | Clamp and method for its use |
| DE19841895A1 (de) | 1998-09-11 | 2000-03-23 | Degussa | Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung |
| WO2000059285A2 (en) * | 1999-04-02 | 2000-10-12 | Du Pont Pharmaceuticals Company | NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE |
| WO2001034172A2 (en) | 1999-11-05 | 2001-05-17 | Vela Pharmaceuticals Inc. | Methods and compositions for treating reward deficiency syndrome |
| BR0108182B1 (pt) * | 2000-02-10 | 2010-06-29 | aparelho para o tratamento de incontinência urinária com suprimento de energia sem fio. | |
| WO2001047441A2 (en) * | 2000-02-14 | 2001-07-05 | Potencia Medical Ag | Penile prosthesis |
| PA8583001A1 (es) * | 2002-09-20 | 2004-04-23 | Hoffmann La Roche | Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b |
| US20040267291A1 (en) * | 2003-06-27 | 2004-12-30 | Byrum Randal T. | Implantable band with non-mechanical attachment mechanism |
| US20040267292A1 (en) * | 2003-06-27 | 2004-12-30 | Byrum Randal T. | Implantable band with transverse attachment mechanism |
-
2003
- 2003-09-17 PA PA20038583001A patent/PA8583001A1/es unknown
- 2003-09-17 PE PE2003000952A patent/PE20050077A1/es not_active Application Discontinuation
- 2003-09-17 TW TW092125618A patent/TWI286132B/zh not_active IP Right Cessation
- 2003-09-17 MY MYPI20033545A patent/MY134480A/en unknown
- 2003-09-18 WO PCT/EP2003/010383 patent/WO2004026826A1/en active Application Filing
- 2003-09-18 US US10/666,594 patent/US7235581B2/en not_active Expired - Fee Related
- 2003-09-18 DE DE60331559T patent/DE60331559D1/de not_active Expired - Lifetime
- 2003-09-18 MY MYPI20033558A patent/MY133332A/en unknown
- 2003-09-18 NZ NZ538048A patent/NZ538048A/en not_active IP Right Cessation
- 2003-09-18 SI SI200331830T patent/SI1542970T1/sl unknown
- 2003-09-18 JP JP2004537119A patent/JP4335140B2/ja not_active Expired - Fee Related
- 2003-09-18 CN CNB038212560A patent/CN100503562C/zh not_active Expired - Fee Related
- 2003-09-18 JP JP2004537121A patent/JP4335142B2/ja not_active Expired - Fee Related
- 2003-09-18 MX MXPA05002880A patent/MXPA05002880A/es active IP Right Grant
- 2003-09-18 NZ NZ538046A patent/NZ538046A/en not_active IP Right Cessation
- 2003-09-18 KR KR1020057004718A patent/KR100676014B1/ko not_active IP Right Cessation
- 2003-09-18 PA PA20038583501A patent/PA8583501A1/es unknown
- 2003-09-18 US US10/667,087 patent/US7151111B2/en active Active
- 2003-09-18 UY UY27991A patent/UY27991A1/es not_active Application Discontinuation
- 2003-09-18 JP JP2004537120A patent/JP4335141B2/ja not_active Expired - Fee Related
- 2003-09-18 BR BR0314299-0A patent/BR0314299A/pt active Search and Examination
- 2003-09-18 ES ES03748052T patent/ES2338646T3/es not_active Expired - Lifetime
- 2003-09-18 GT GT200300205A patent/GT200300205A/es unknown
- 2003-09-18 KR KR1020057004683A patent/KR100676015B1/ko not_active IP Right Cessation
- 2003-09-18 PL PL03376019A patent/PL376019A1/xx not_active Application Discontinuation
- 2003-09-18 EP EP03748052A patent/EP1542969B1/en not_active Expired - Lifetime
- 2003-09-18 CA CA002498335A patent/CA2498335A1/en not_active Abandoned
- 2003-09-18 MX MXPA05002878A patent/MXPA05002878A/es active IP Right Grant
- 2003-09-18 BR BR0314314-7A patent/BR0314314A/pt not_active IP Right Cessation
- 2003-09-18 EP EP03750564A patent/EP1542970B1/en not_active Expired - Lifetime
- 2003-09-18 BR BR0314631-6A patent/BR0314631A/pt not_active IP Right Cessation
- 2003-09-18 DE DE60333202T patent/DE60333202D1/de not_active Expired - Lifetime
- 2003-09-18 PT PT03750564T patent/PT1542970E/pt unknown
- 2003-09-18 AU AU2003267381A patent/AU2003267381B2/en not_active Ceased
- 2003-09-18 AR ARP030103385A patent/AR041299A1/es not_active Application Discontinuation
- 2003-09-18 CA CA2498785A patent/CA2498785C/en not_active Expired - Fee Related
- 2003-09-18 AT AT03748052T patent/ATE459601T1/de active
- 2003-09-18 PL PL03376018A patent/PL376018A1/xx not_active Application Discontinuation
- 2003-09-18 EP EP03757866A patent/EP1542971A1/en not_active Withdrawn
- 2003-09-18 CA CA2496756A patent/CA2496756C/en not_active Expired - Fee Related
- 2003-09-18 US US10/667,088 patent/US7037935B2/en not_active Expired - Fee Related
- 2003-09-18 WO PCT/EP2003/010356 patent/WO2004026825A1/en active Application Filing
- 2003-09-18 PE PE2003000958A patent/PE20050079A1/es active IP Right Grant
- 2003-09-18 CN CNB038217678A patent/CN100400509C/zh not_active Expired - Fee Related
- 2003-09-18 AR ARP030103384A patent/AR041298A1/es unknown
- 2003-09-18 PL PL376021A patent/PL216030B1/pl unknown
- 2003-09-18 TW TW092125735A patent/TWI337604B/zh not_active IP Right Cessation
- 2003-09-18 TW TW092125746A patent/TWI331994B/zh not_active IP Right Cessation
- 2003-09-18 WO PCT/EP2003/010384 patent/WO2004026827A1/en active Application Filing
- 2003-09-18 GT GT200300206A patent/GT200300206A/es unknown
- 2003-09-18 RU RU2005111969/04A patent/RU2323209C2/ru not_active IP Right Cessation
- 2003-09-18 AU AU2003273901A patent/AU2003273901B2/en not_active Ceased
- 2003-09-18 UY UY27990A patent/UY27990A1/es not_active Application Discontinuation
- 2003-09-18 MY MYPI20033559A patent/MY135696A/en unknown
- 2003-09-18 RU RU2005111974/04A patent/RU2336267C2/ru not_active IP Right Cessation
- 2003-09-18 RU RU2005111968/04A patent/RU2336268C2/ru not_active IP Right Cessation
- 2003-09-18 PE PE2003000956A patent/PE20050078A1/es not_active Application Discontinuation
- 2003-09-18 MX MXPA05002881A patent/MXPA05002881A/es active IP Right Grant
- 2003-09-18 AR ARP030103383A patent/AR041297A1/es unknown
- 2003-09-18 KR KR1020057004699A patent/KR100681586B1/ko active IP Right Grant
- 2003-09-18 PA PA20038583601A patent/PA8583601A1/es unknown
- 2003-09-18 ES ES03750564T patent/ES2344557T3/es not_active Expired - Lifetime
- 2003-09-18 AU AU2003270213A patent/AU2003270213B8/en not_active Ceased
- 2003-09-18 CN CNB038219522A patent/CN100383118C/zh not_active Expired - Fee Related
- 2003-09-18 DK DK03750564.1T patent/DK1542970T3/da active
- 2003-09-18 GT GT200300204A patent/GT200300204A/es unknown
- 2003-09-18 BR BRPI0314631-6A patent/BRPI0314631B1/pt unknown
- 2003-09-18 AT AT03750564T patent/ATE472530T1/de active
- 2003-09-18 JO JO2003116A patent/JO2605B1/en active
- 2003-09-18 NZ NZ538049A patent/NZ538049A/en unknown
- 2003-09-18 JO JO2003115A patent/JO2604B1/en active
- 2003-09-19 UY UY27993A patent/UY27993A1/es not_active Application Discontinuation
-
2005
- 2005-02-08 NO NO20050652A patent/NO329754B1/no not_active IP Right Cessation
- 2005-02-08 NO NO20050665A patent/NO330012B1/no not_active IP Right Cessation
- 2005-02-08 ZA ZA200501137A patent/ZA200501137B/xx unknown
- 2005-02-09 NO NO20050701A patent/NO20050701L/no not_active Application Discontinuation
- 2005-02-14 ZA ZA200501311A patent/ZA200501311B/en unknown
- 2005-02-22 ZA ZA200501557A patent/ZA200501557B/xx unknown
- 2005-03-18 HR HR20050261A patent/HRP20050261A2/hr not_active Application Discontinuation
- 2005-03-18 HR HR20050262A patent/HRP20050262A2/xx not_active Application Discontinuation
- 2005-03-18 HR HRP20050263AA patent/HRP20050263B1/hr not_active IP Right Cessation
-
2006
- 2006-01-05 US US11/325,747 patent/US7122562B2/en not_active Expired - Fee Related
- 2006-03-20 HK HK06103475A patent/HK1083498A1/xx not_active IP Right Cessation
- 2006-03-20 HK HK06103476.1A patent/HK1083499A1/xx not_active IP Right Cessation
- 2006-03-20 HK HK06103481A patent/HK1084383A1/xx not_active IP Right Cessation
-
2010
- 2010-08-20 CY CY20101100770T patent/CY1110745T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO330012B1 (no) | Pyrrolidonderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat inneholdende slike, slike forbindelser for behandling av sykdom samt anvendelse av slike for fremstilling av medikament for behandling av sykdom | |
| US7485731B2 (en) | Method for preparing enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives | |
| EP1761480A2 (en) | New mao-b inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |